Quantcast
Home > Quotes > XERS

Xeris Pharmaceuticals, Inc. Common Stock (XERS) Quote & Summary Data

XERS 
$20.19
*  
0.03
0.15%
Get XERS Alerts
*Delayed - data as of Dec. 13, 2018  -  Find a broker to begin trading XERS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
25
Today's High / Low
$ 20.50 / $ 20
Share Volume
41,183
50 Day Avg. Daily Volume
55,321
Previous Close
$ 20.22
52 Week High / Low
$ 27.9826 / $ 15.75
Market Cap
421,306,264
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-2.38

Intraday Chart

Shares Traded

Share Volume:
41,183
50 Day Avg. Daily Volume:
55,321

Trading Range

The current last sale of $20.19 is 28.19% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 20.50 $ 27.9826
 Low: $ 20 $ 15.75

Company Description (as filed with the SEC)

We are a specialty pharmaceutical company leveraging our novel non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize ready-to-use injectable and infusible drug formulations. We have developed a ready-to-use, room-temperature stable liquid glucagon formulation that, unlike any currently available products, can be administered without any preparation or reconstitution. Our lead product candidate, Glucagon Rescue Pen, delivers ready-to-use glucagon via a commercially-available auto-injector for the treatment of severe hypoglycemia, a potentially life-threatening condition, in people with diabetes. We have completed three Phase 3 clinical trials for our Glucagon Rescue Pen and expect to submit a New Drug Application, or NDA, to the U.S. Food and Drug Administration, or the FDA, in the third quarter of 2018.  ... More ...  


Risk Grade

Where does XERS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 20.25
Open Date:
Dec. 13, 2018
Close Price:
$ 20.19
Close Date:
Dec. 13, 2018

Consensus Recommendation

Analyst Info